Weimou Biological Technology(Shanghai)Co., Ltd.
维眸生物
Weimou Biological Technology(Shanghai)Co., Ltd.
Biotech/Healthcare
Weimo Biotech is a dry eye disease biopharmaceutical developer focused on the R&D of new drugs for treating eye diseases. Its main product is the dry eye treatment drug Lifitegrast, which has been approved by the FDA, and standardized preclinical pharmacology and toxicology evaluations of the new…
Latest round: Series D (2021)
Source: ChinaBulls — chinabulls.com
Last updated 2021-04-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.